Finanzas de Anixa Biosciences Inc (ANIX)ANIXAnixa Biosciences Inc

Anixa Biosciences Inc (ANIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Flat-Panel Display, accounting for 98.9% of total sales, equivalent to $246.67K. Another important revenue stream is Encryption Products. Understanding this composition is critical for investors evaluating how ANIX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Anixa Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -66.84%, provide a clear picture of how effectively ANIX converts its operational activities into shareholder value.

In the context of the broader market, ANIX competes directly with industry leaders such as AVXL and VYGR. With a market capitalization of $105.32M, it holds a significant position in the sector. When comparing efficiency, ANIX's gross margin of N/A stands against AVXL's N/A and VYGR's 100.00%. Such benchmarking helps identify whether Anixa Biosciences Inc is trading at a premium or discount relative to its financial performance.

Anixa has reported negative net income consistently, with the latest quarter showing a loss of -2,606,000 USD. The current ratio is high at 8.54, indicating good short-term liquidity despite ongoing losses. The company has a price-to-book ratio of 7.495, suggesting that the stock is trading at a premium relative to its book value, which may concern some investors.